Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Revance Therapeutics revenue
Revance Therapeutics's revenue is $234.0 million.
What is Revance Therapeutics's revenue?
- Revance Therapeutics's revenue growth from 2012 to 2023 is 32,541.56%.
- Revance Therapeutics has 170 employees, and the revenue per employee ratio is $1,376,705.
- Revance Therapeutics's peak quarterly revenue was $69.7M in 2023(q4).
- Revance Therapeutics peak revenue was $234.0M in 2023.
- Revance Therapeutics annual revenue for 2022 was 132.6M, 70.4% growth from 2021.
- Revance Therapeutics annual revenue for 2023 was 234.0M, 76.55% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Revance Therapeutics historical revenue
Revance Therapeutics's peak revenue was $234.0M in 2023. The peak quarterly revenue was $69.7M in 2023(q4).
Revance Therapeutics's revenue increased from $717.0k in 2012 to $234.0M currently. That's a 32,541.56% change in annual revenue.
Revance Therapeutics annual revenue
Revance Therapeutics annual revenue over time
| Fiscal year / year | Revance Therapeutics revenue |
|---|---|
| 2012 | $717,000 |
| 2013 | $617,000 |
| 2014 | $383,000 |
| 2015 | $300,000 |
| 2016 | $300,000 |
| 2017 | $262,000 |
| 2018 | $3.7M |
| 2019 | $413,000 |
| 2020 | $15.3M |
| 2021 | $77.8M |
| 2022 | $132.6M |
| 2023 | $234.0M |
How accurately did Revance Therapeutics' revenue projections match actual performance?
Revance Therapeutics annual growth
Revance Therapeutics saw the greatest revenue growth in 2020, when revenue increased by 3,610.65%.
Revance Therapeutics had the lowest revenue growth in 2019, when revenue changed by -88.92%.
Revance Therapeutics annual growth rate over time
| Year | Revance Therapeutics growth |
|---|---|
| 2013 | -14%↓ |
| 2014 | -38%↓ |
| 2015 | -22%↓ |
| 2016 | 0%↓ |
| 2017 | -13%↓ |
| 2018 | 1323%↑ |
| 2019 | -89%↓ |
| 2020 | 3611%↑ |
| 2021 | 408%↑ |
| 2022 | 70%↑ |
| 2023 | 77%↑ |
Revance Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Revance Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | - | $309,000 |
| 2014 | $158,000 | $75,000 | $75,000 | $75,000 |
| 2015 | $75,000 | $75,000 | $75,000 | $75,000 |
| 2016 | $75,000 | $75,000 | $75,000 | $75,000 |
| 2017 | $75,000 | $75,000 | $75,000 | $37,000 |
| 2018 | $193,000 | $686,000 | $2.4M | $487,000 |
| 2019 | $278,000 | - | $46,000 | $89,000 |
| 2020 | $58,000 | $299,000 | $3.8M | $11.1M |
| 2021 | $13.3M | $18.8M | $19.7M | $26.0M |
| 2022 | $25.3M | $28.4M | $29.0M | $49.9M |
| 2023 | $45.8M | $54.4M | $54.1M | $69.7M |
| 2024 | $51.9M | $65.4M | $59.9M | - |
Revance Therapeutics jobs nearby
Do you work at Revance Therapeutics?
Did Revance Therapeutics meet its revenue projections?
Revance Therapeutics financial information
| CEO | Mark J. Foley |
| Company Type | Public |
| Employees Number | 170 |
| Date Founded | 1999 |
| Headquarters | Newark, California |
| Number of Locations | 5 |
| Revenue | $234.0M |
| Net Income | -$356,422,000 |
| Gross Proft | $159.7M (2023) |
| EBITDA | ($311.5M) (2023) |
| Tax Rate | -0.0% |
| Total Assets | $581,900,000 |
| Ticker | RVNC |
Revance Therapeutics jobs you might like
Revance Therapeutics financing
Revance Therapeutics received early financing of $1.8M on 2003-05-27.
| Series | Round size | Date |
|---|---|---|
| Series A | $1.8M | 05/2003 |
| Series B | $13M | 04/2004 |
| Series C | $43.2M | 12/2007 |
| Debt Financing | $8M | 11/2008 |
| Series D | $25.6M | 12/2009 |
| Series D | $45M | 06/2011 |
| Series E | $33M | 04/2013 |
| Series Unknown | $10M | 10/2013 |
| Post Ipo Equity | $241M | 02/2014 |
| Post Ipo Equity | $126M | 11/2015 |
| Post Ipo Equity | $167.1M | 12/2017 |
| Post Ipo Equity | $115M | 01/2019 |
| Post Ipo Equity | $110.5M | 12/2019 |
| Post Ipo Debt | $250M | 02/2020 |
| Post Ipo Debt | $300M | 03/2022 |
Revance Therapeutics investors
| Investors | Security type |
|---|---|
| Vivo Capital | Series B |
| Essex Woodlands Health Ventures | Series B |
| Technology Partners | Series B |
| MEDICIS PHARMACEUTICAL CORP | Series C |
| Vivo Capital | Series C |
| Palo Alto Investors | Series C |
| Essex Woodlands Health Ventures | Series C |
| Technology Partners | Series C |
| Shepherd Ventures | Series C |
| Leader Ventures | Debt Financing |
| Horizon Technology Finance | Debt Financing |
| EDBI Pte Ltd | Series D |
| Vivo Capital | Series D |
| Pac Link | Series D |
| Palo Alto Investors | Series D |
| Essex Woodlands Health Ventures | Series D |
| Technology Partners | Series D |
| Shepherd Ventures | Series D |
| CNF Investments LLC | Series D |
| Vivo Capital | Series D |
| Palo Alto Investors | Series D |
| Essex Woodlands Health Ventures | Series D |
| Technology Partners | Series D |
| Shepherd Ventures | Series D |
| NovaQuest Capital Management | Series D |
| Delphi Ventures | Series E |
| Essex Woodlands Health Ventures | Series E |
| IQVIA Holdings Inc. | Series E |
| Athyrium Capital Management LP | Post Ipo Debt |
Revance Therapeutics competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| SIGA Technologies | $71,494 | $115.5M | 43 | - |
| Nanotherapeutics, Inc. | $71,678 | - | - | - |
| MAP Pharmaceuticals | $87,034 | $23.1M | 137 | - |
| Acusphere | $76,389 | - | 118 | - |
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Ariad Pharmaceuticals | $94,078 | $118.8M | 380 | - |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 265 |
| Hoffmann-LA Roche Inc | $93,461 | $60.9B | 101,200 | 112 |
| Emisphere Technologies | $71,999 | $1.2M | 76 | - |
| PTC Therapeutics | $92,986 | $806.8M | 517 | 11 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Revance Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Revance Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Revance Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Revance Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Revance Therapeutics. The data presented on this page does not represent the view of Revance Therapeutics and its employees or that of Zippia.
Revance Therapeutics may also be known as or be related to REVANCE THERAPEUTICS INC., Revance Therapeutics, Revance Therapeutics Inc and Revance Therapeutics, Inc.